Waldenstrom macroglobulinemia (WM) is a rare form of non-Hodgkin’s lymphoma characterized by an overproduction of abnormal white blood cells. It’s a slow-growing type of blood cell cancer that affects ...
The Conversation: Maladie du foie gras : décoder nos gènes pour mieux la prévenir
Maladie du foie gras : décoder nos gènes pour mieux la prévenir
Treatment decisions for Waldenstrom’s macroglobulinemia should consider comorbidities, lifestyle, and cost, as chemotherapy and BTK inhibitors show similar response rates. BTK inhibitors, including ...
Business Insider: Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression ...
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression ...
Cure Today: Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results
CLR 131 shows promise in treating relapsed/refractory Waldenstrom’s macroglobulinemia, targeting B-cell malignancies with iodine-131 delivery. The trial will enroll 50 patients, administering up to ...
Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results
Seeking Alpha: Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Nasdaq: Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia